BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 17984685)

  • 1. Intrathecal delivery of hepatocyte growth factor from amyotrophic lateral sclerosis onset suppresses disease progression in rat amyotrophic lateral sclerosis model.
    Ishigaki A; Aoki M; Nagai M; Warita H; Kato S; Kato M; Nakamura T; Funakoshi H; Itoyama Y
    J Neuropathol Exp Neurol; 2007 Nov; 66(11):1037-44. PubMed ID: 17984685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hepatocyte growth factor therapy for amyotrophic lateral sclerosis].
    Aoki M
    Brain Nerve; 2012 Mar; 64(3):245-54. PubMed ID: 22402718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Restorative therapy in amyotrophic lateral sclerosis].
    Aoki M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Nov; 32(5-6):287-92. PubMed ID: 23373317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of motor neuron restorative therapy in amyotrophic lateral sclerosis using hepatocyte growth factor].
    Aoki M; Warita H; Suzuki N; Itoyama Y
    Rinsho Shinkeigaku; 2009 Nov; 49(11):814-7. PubMed ID: 20030218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic benefits of intrathecal protein therapy in a mouse model of amyotrophic lateral sclerosis.
    Ohta Y; Kamiya T; Nagai M; Nagata T; Morimoto N; Miyazaki K; Murakami T; Kurata T; Takehisa Y; Ikeda Y; Asoh S; Ohta S; Abe K
    J Neurosci Res; 2008 Oct; 86(13):3028-37. PubMed ID: 18543336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neural stem cells LewisX+ CXCR4+ modify disease progression in an amyotrophic lateral sclerosis model.
    Corti S; Locatelli F; Papadimitriou D; Del Bo R; Nizzardo M; Nardini M; Donadoni C; Salani S; Fortunato F; Strazzer S; Bresolin N; Comi GP
    Brain; 2007 May; 130(Pt 5):1289-305. PubMed ID: 17439986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Amyotrophic lateral sclerosis with the SOD1 mutations].
    Aoki M; Warita H; Itoyama Y
    Rinsho Shinkeigaku; 2008 Nov; 48(11):966-9. PubMed ID: 19198133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic benefits of putrescine-modified catalase in a transgenic mouse model of familial amyotrophic lateral sclerosis.
    Reinholz MM; Merkle CM; Poduslo JF
    Exp Neurol; 1999 Sep; 159(1):204-16. PubMed ID: 10486188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Regenerative therapies for amyotrophic lateral sclerosis using hepatocyte growth factor].
    Aoki M; Warita H; Suzuki N; Kato M; Itoyama Y
    Rinsho Shinkeigaku; 2011 Nov; 51(11):1195-8. PubMed ID: 22277532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocyte growth factor promotes endogenous repair and functional recovery after spinal cord injury.
    Kitamura K; Iwanami A; Nakamura M; Yamane J; Watanabe K; Suzuki Y; Miyazawa D; Shibata S; Funakoshi H; Miyatake S; Coffin RS; Nakamura T; Toyama Y; Okano H
    J Neurosci Res; 2007 Aug; 85(11):2332-42. PubMed ID: 17549731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Application of Hepatocyte Growth Factor for Amyotrophic Lateral Sclerosis].
    Aoki M; Warita H; Kato M; Suzuki N
    Brain Nerve; 2019 Nov; 71(11):1253-1260. PubMed ID: 31722311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neurotrophic factors and amyotrophic lateral sclerosis (ALS)--therapeutic potential of a new neurotrophic factor: HGF in ALS].
    Funakoshi H; Nakamura T
    No To Shinkei; 2003 Oct; 55(10):841-5. PubMed ID: 14635512
    [No Abstract]   [Full Text] [Related]  

  • 13. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice.
    Ryu H; Smith K; Camelo SI; Carreras I; Lee J; Iglesias AH; Dangond F; Cormier KA; Cudkowicz ME; Brown RH; Ferrante RJ
    J Neurochem; 2005 Jun; 93(5):1087-98. PubMed ID: 15934930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IGF-1:tetanus toxin fragment C fusion protein improves delivery of IGF-1 to spinal cord but fails to prolong survival of ALS mice.
    Chian RJ; Li J; Ay I; Celia SA; Kashi BB; Tamrazian E; Matthews JC; Bronson RT; Rossomando A; Pepinsky RB; Fishman PS; Brown RH; Francis JW
    Brain Res; 2009 Sep; 1287():1-19. PubMed ID: 19563785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with trichostatin A initiated after disease onset delays disease progression and increases survival in a mouse model of amyotrophic lateral sclerosis.
    Yoo YE; Ko CP
    Exp Neurol; 2011 Sep; 231(1):147-59. PubMed ID: 21712032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical translation of hepatocyte growth factor for amyotrophic lateral sclerosis].
    Warita H; Kato M; Suzuki N; Itoyama Y; Aoki M
    Rinsho Shinkeigaku; 2012; 52(11):1214-7. PubMed ID: 23196568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyotrophic lateral sclerosis: evidence for intact hepatocyte growth factor/met signalling axis.
    Kern MA; Friese M; Grundstrom E; Korhonen L; Wallin A; Aquilonius SM; Askmark H; Schirmacher P; Lindholm D
    Cytokine; 2001 Sep; 15(6):315-9. PubMed ID: 11594798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-like growth factor-I: potential for treatment of motor neuronal disorders.
    Lewis ME; Neff NT; Contreras PC; Stong DB; Oppenheim RW; Grebow PE; Vaught JL
    Exp Neurol; 1993 Nov; 124(1):73-88. PubMed ID: 8282084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Slow and selective death of spinal motor neurons in vivo by intrathecal infusion of kainic acid: implications for AMPA receptor-mediated excitotoxicity in ALS.
    Sun H; Kawahara Y; Ito K; Kanazawa I; Kwak S
    J Neurochem; 2006 Aug; 98(3):782-91. PubMed ID: 16893420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic elevation of extracellular glutamate due to transport blockade is innocuous for spinal motoneurons in vivo.
    Tovar-Y-Romo LB; Santa-Cruz LD; Zepeda A; Tapia R
    Neurochem Int; 2009; 54(3-4):186-91. PubMed ID: 19100799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.